Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (28 quarters reported)
$207M in Q4 2018 → — now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| NS No Securities | NaN% | Unchanged | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2025 · filed November 12, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 06, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amgen Inc | Exited | −60,000 | −$18.7M | — |
| Blueprint Medicines Corp | Exited | −83,926 | −$7.43M | — |
| AP Arrowhead Pharmaceuticals In | Exited | −550,130 | −$7.01M | — |
| Protagonist Therapeutics Inc | Exited | −81,692 | −$3.95M | — |
| Kymera Therapeutics Inc | Exited | −138,521 | −$3.79M | — |
| Precision Biosciences Inc | Exited | −726,149 | −$3.46M | — |
| Arvinas Inc | Exited | −360,766 | −$2.53M | — |
| Regenxbio Inc | Exited | −271,302 | −$1.94M | — |
| Adicet Bio Inc | Exited | −2,456,194 | −$1.85M | — |
| Bicycle Therapeutics PLC | Exited | −171,695 | −$1.46M | — |
Showing the 10 largest of 14 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Amgen Inc | Added | +35,000 | +$10.9M | 33.5% |
| Blueprint Medicines Corp | Trimmed | −45,674 | −$4.04M | 13.3% |
| Silence Therapeutics PLC | Exited | −367,214 | −$2.53M | — |
| AP Arrowhead Pharmaceuticals In | Trimmed | −157,459 | −$2.01M | 12.6% |
| AP Arrowhead Pharmaceuticals In | Exited | −75,000 | −$1.41M | — |
| Kymera Therapeutics Inc | Trimmed | −45,000 | −$1.23M | 6.8% |
| Zymeworks Inc | New | +84,482 | +$1.01M | 1.8% |
| Precision Biosciences Inc | Added | +189,773 | +$905K | 6.2% |
| Regenxbio Inc | Trimmed | −75,000 | −$536K | 3.5% |
| Bicycle Therapeutics PLC | Trimmed | −50,216 | −$426K | 2.6% |
Showing the 10 largest of 15 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | Exited | −75,000 | −$43M | — |
| Amgen Inc | New | +25,000 | +$6.52M | 9.8% |
| Merus N V | Exited | −117,855 | −$5.89M | — |
| Regenxbio Inc | Trimmed | −584,406 | −$4.52M | 4.0% |
| Protagonist Therapeutics Inc | New | +76,592 | +$2.96M | 4.5% |
| AP Arrowhead Pharmaceuticals In | Trimmed | −88,224 | −$1.66M | 20.1% |
| AP Arrowhead Pharmaceuticals In | New | +75,000 | +$1.41M | 2.1% |
| Sutro Biopharma Inc | Trimmed | −762,000 | −$1.4M | — |
| Arvinas Inc | Trimmed | −60,000 | −$1.15M | 9.5% |
| Kymera Therapeutics Inc | Trimmed | −25,222 | −$1.01M | 11.1% |
Showing the 10 largest of 16 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | New | +75,000 | +$43M | 32.6% |
| Kymera Therapeutics Inc | Trimmed | −120,000 | −$5.68M | 7.5% |
| Silence Therapeutics PLC | Trimmed | −183,000 | −$3.33M | 4.4% |
| AP Arrowhead Pharmaceuticals In | Trimmed | −112,661 | −$2.18M | 11.7% |
| Immatics N.v | Added | +133,502 | +$1.52M | 2.9% |
| Merus N V | Trimmed | −30,254 | −$1.51M | 4.5% |
| Arvinas Inc | Trimmed | −40,000 | −$985K | 7.3% |
| Blueprint Medicines Corp | Added | +10,000 | +$925K | 8.7% |
| Bicycle Therapeutics PLC | Added | +25,219 | +$571K | 3.1% |
| Regenxbio Inc | Added | +24,460 | +$257K | 7.4% |
Showing the 10 largest of 11 changes.
quarter ended June 30, 2024 · filed August 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Blueprint Medicines Corp | Trimmed | −67,551 | −$7.28M | 11.9% |
| Merus N V | Trimmed | −107,000 | −$6.33M | 8.4% |
| Bicycle Therapeutics PLC | New | +156,692 | +$3.17M | 3.1% |
| Adicet Bio Inc | New | +2,531,194 | +$3.06M | 3.0% |
| Immatics N.v | New | +200,000 | +$2.32M | 2.2% |
| Kymera Therapeutics Inc | Trimmed | −60,000 | −$1.79M | 9.5% |
| Silence Therapeutics PLC | Trimmed | −74,000 | −$1.41M | 9.2% |
| Sutro Biopharma Inc | Trimmed | −402,968 | −$1.18M | 2.2% |
| Repare Therapeutics Inc | Added | +323,661 | +$1.07M | 3.0% |
| Arvinas Inc | Added | +23,000 | +$612K | 11.0% |
Showing the 10 largest of 11 changes.
quarter ended March 31, 2024 · filed May 15, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kymera Therapeutics Inc | Trimmed | −492,594 | −$19.8M | 11.7% |
| SB S&P Biotech ETF Tr | Exited | −200,000 | −$17.9M | — |
| Silence Therapeutics PLC | Trimmed | −469,070 | −$10.1M | 9.3% |
| Blueprint Medicines Corp | Trimmed | −72,676 | −$6.89M | 13.0% |
| Precision Biosciences Inc | New | +385,440 | +$5.23M | 3.9% |
| Merus N V | Trimmed | −100,000 | −$4.5M | 8.6% |
| Sutro Biopharma Inc | Added | +744,817 | +$4.21M | 4.9% |
| Arvinas Inc | Trimmed | −83,387 | −$3.44M | 12.6% |
| Regenxbio Inc | Added | +103,824 | +$2.19M | 14.3% |
quarter ended December 31, 2023 · filed February 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SB S&P Biotech ETF Tr | New | +200,000 | +$17.9M | 11.1% |
| Blueprint Medicines Corp | Trimmed | −124,263 | −$11.5M | 14.6% |
| Silence Therapeutics PLC | Trimmed | −268,949 | −$4.67M | 11.3% |
| Repare Therapeutics Inc | New | +633,271 | +$4.62M | 2.9% |
| C4 Therapeutics Inc | Exited | −1,990,334 | −$3.7M | — |
| Kymera Therapeutics Inc | Added | +99,118 | +$2.52M | 14.0% |
| Merus N V | Trimmed | −75,000 | −$2.06M | 6.1% |
| Genmab A/s | Exited | −52,148 | −$1.84M | — |
| Argenx Se | Exited | −3,715 | −$1.83M | — |
| Sutro Biopharma Inc | New | +420,649 | +$1.8M | 1.1% |
Showing the 10 largest of 13 changes.
Loading...
